Trial Profile
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Feb 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 09 Dec 2023 Trial design, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium